Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01215500 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT01215500 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 63 participants.
The verdict
NCT01215500, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
Patients with metastatic cancer are generally treated with chemotherapy, which has improved median survival compared to best supportive care. Despite this, patients continue to have persistent disease at sites that were initially involved with cancer. Radiation therapy is an effective modality for treating localized cancer but generally has been only used for palliation of symptoms once a patient develops metastatic disease. Since patients often have persistent disease after chemotherapy, the goal of this trial is to use increasing doses of radiation therapy to all sites of involved disease in order to determine the safety and efficacy of hypofractionated radiation therapy. The purpose of this study is to establish a maximum tolerated dose, dose-limiting toxicities, and recommended phase 2 dose of hypofractionated radiation therapy.
Interventions
- RADIATION Hypofractionated RT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2005-01 |
| Est. Completion | 2018-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01215500
The ClinicalTrials.gov registry entry for NCT01215500 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hypofractionated RT is the first listed.
NCT01215500 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01215500 about?
NCT01215500 is a clinical study titled "Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer". Patients with metastatic cancer are generally treated with chemotherapy, which has improved median survival compared to best supportive care. Despite this, patients continue to have persistent disease at sites that were initially involved with cancer. Radiation therapy is an effective modality for t...
What is the current status of trial NCT01215500?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2005-01. Estimated completion is 2018-03.
What interventions are being tested in trial NCT01215500?
The interventions under investigation include: Hypofractionated RT (RADIATION).
Who is sponsoring clinical trial NCT01215500?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.